Printer Friendly

Applied Biosystems Creates New Software Development Community to Encourage Innovation in Life Science Technologies; Program Provides Scientists and Software Developers Access to New Tools for Building Life Science Research Applications.

FOSTER CITY, Calif. -- Applied Biosystems (NYSE:ABI), an Applera Corporation business, today announced the launch of a new software development community, designed to encourage innovation in life science research software applications. As part of this initiative, Applied Biosystems said it will provide life scientists and independent software vendors (ISVs) open access to its genetic analysis data file format and a data file converter to facilitate the development of next generation bioinformatics applications that can advance productivity and data sharing on Applied Biosystems' industry leading genetic analyzers and real-time PCR sequence detection systems.

As demand increases for software applications that address the challenges associated with generating, analyzing and managing research data in emerging areas of life science research such as DNA fragment, RNA, and genomic copy number analysis, a more open and collaborative software development approach has become necessary. Open technologies have the potential to revolutionize how biomedical researchers conduct scientific experiments and how they are extended beyond the laboratory to involve activities such as the cross-referencing of research data, patient histories and clinical trial results.

"Applied Biosystems understands that in order for the life sciences community to ultimately achieve its goal of targeted medicine, an environment of collaboration and innovation is required," said Dennis A. Gilbert, Ph.D., chief scientific officer for Applied Biosystems. "Our mission is to create a more collaborative environment that provides an open and widely accessible pool of resources that will enable customers and ISVs to develop and bring to market innovative new applications that will allow the research community to find more answers, faster and more cost effectively."

Applied Biosystems has already initiated a number of new collaborations with leading ISVs directly and through organizations such as the BioIT Alliance, a cross-industry working group of pharmaceutical, biotech, hardware, and software companies exploring new ways to share complex biomedical data and collaborate among multi-disciplinary teams to speed the pace of discovery in the life sciences.

Geospiza, a leading developer of information technology solutions to automate genetic testing, analysis and data production, has developed a new tool that improves data analysis workflow and provides better sharing of research and discovery project data across workgroups using the Geospiza Finch Suite, a leading software platform that facilities clinical and pre-clinical genetic testing based on DNA sequence analysis.

"Geospiza is very excited to be one of the first companies to join the Applied Biosystems software development community," said Kevin Banks, Ph.D., vice president of business development at Geospiza. "Applied Biosystems and Geospiza already have a strong track record of working together to deliver best in class information technology solutions for DNA sequencing. With access to new tools through Applied Biosystems' software development community, Geospiza will now have more opportunities to expand our IT platform to support emerging applications in DNA fragment and SNP analysis."

The software development community represents the next step in Applied Biosystems' commitment to fostering innovation in life science technologies for its industry leading genetic analyzers and real-time PCR sequence detection systems. Through its joint venture with MDS Sciex, Applied Biosystems is also enabling innovation in the development of new applications for mass spectrometry systems used in drug discovery and development, protein analysis, and in food, beverage and environmental testing.

The Applied Biosystems/MDS SCIEX mass spectrometer software platforms provide data converters and application development tools that enable life scientists and ISVs to develop plug-ins and instrument controls that extend the functionally and productivity of mass spectrometry systems. These tools have been successfully used to develop applications such as liquid chromatography device drivers and high-throughput absorption, distribution, metabolism, and excretion compound profiling applications critical to the drug discovery and development process. Access to these tools is provided to all licensed users of the Applied Biosystems/MDS SCIEX mass spectrometer software platforms.

Life scientists and software developers interested in learning more about the Applied Biosystems software development community may visit the web site located at The site contains a collection of information resources including sample data files and free software tools, such as the Data File Converter which enables users to export data from the .abl (sequencing), .fsa (fragment analysis) and .sds (real-time PCR) formats to text and XML compatible files.

For more information about the Applied Biosystems/MDS SCIEX software platforms, please visit

About Applera Corporation and Applied Biosystems

Applera Corporation consists of two operating groups. The Applied Biosystems Group serves the life science industry and research community by developing and marketing instrument-based systems, consumables, software, and services. Customers use these tools to analyze nucleic acids (DNA and RNA), small molecules, and proteins to make scientific discoveries and develop new pharmaceuticals. Applied Biosystems' products also serve the needs of some markets outside of life science research, which we refer to as "applied markets," such as the fields of: human identity testing (forensic and paternity testing); biosecurity, which refers to products needed in response to the threat of biological terrorism and other malicious, accidental, and natural biological dangers; and quality and safety testing, for example in food and the environment. Applied Biosystems is headquartered in Foster City, CA, and reported sales of over $1.9 billion during fiscal 2006. The Celera Genomics Group is primarily a molecular diagnostics business that is using proprietary genomics and proteomics discovery platforms to identify and validate novel diagnostic markers, and is developing diagnostic products based on these markers as well as other known markers. Celera Genomics maintains a strategic alliance with Abbott Laboratories for the development and commercialization of molecular, or nucleic acid-based, diagnostic products, and it is also developing new diagnostic products outside of this alliance. Through its genomics and proteomics research efforts, Celera Genomics is also discovering and validating therapeutic targets, and it is seeking strategic partnerships to develop therapeutic products based on these discovered targets. Information about Applera Corporation, including reports and other information filed by the company with the Securities and Exchange Commission, is available at, or by telephoning 800.762.6923. Information about Applied Biosystems is available at

Applied Biosystems Forward Looking Statements

Certain statements in this press release are forward-looking. These may be identified by the use of forward-looking words or phrases such as "believe," "expect," and "planned," among others. These forward-looking statements are based on Applera Corporation's current expectations. The Private Securities Litigation Reform Act of 1995 provides a "safe harbor" for such forward-looking statements. In order to comply with the terms of the safe harbor, Applera Corporation notes that a variety of factors could cause actual results and experience to differ materially from the anticipated results or other expectations expressed in such forward-looking statements. These factors include but are not limited to: (1) risks associated with lawsuits, arbitrations, investigations, and other legal actions with private parties and governmental entities, particularly involving claims for infringement of patents and other intellectual property rights, and the possibility that Applied Biosystems may need to license intellectual property from third parties to avoid or settle such claims; and (2) other factors that might be described from time to time in Applera Corporation's filings with the Securities and Exchange Commission. All information in this press release is as of the date of the release, and Applera does not undertake any duty to update this information, including any forward-looking statements, unless required by law.

(C)Copyright 2006. Applera Corporation. All rights reserved. Applied Biosystems and Celera are registered trademarks and Applera and Celera Genomics are trademarks of Applera Corporation or its subsidiaries in the U.S. and/or certain other countries.
COPYRIGHT 2006 Business Wire
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2006, Gale Group. All rights reserved. Gale Group is a Thomson Corporation Company.

Article Details
Printer friendly Cite/link Email Feedback
Publication:Business Wire
Geographic Code:1USA
Date:Aug 28, 2006
Previous Article:Desert Capital REIT, Inc. Announces Second Quarter 2006 Results.
Next Article:Senforce Now Shipping Endpoint Security Suite (ESS) 3.2 with New Removable Storage Policy Controls; Senforce ESS 3.2 Solves Data Security Issues from...

Related Articles
Applied Biosystems/MDS Sciex's New Automated Testing Solution Improves Food Contaminant Detection; New Software-based System Transforms Routine Food...
Applied Biosystems/MDS Sciex Accelerates Drug Discovery with New Pharmaceutical Application.
Applied Biosystems Joins the Genographic Project to Support Landmark Population Genetics Study Mapping the History of Human Migration.
Applied Biosystems and GeneGo Collaborate to Advance Understanding of Tissue Gene Expression; GeneGo Integrates Applied Biosystems Tissue Gene...
Geospiza Expands Collaboration with Applied Biosystems to Integrate Genetic Analysis Products.
Applied Biosystems Introduces New DNA Technologies that Address Major Challenges Facing Forensic Scientists.
Applied Biosystems/MDS SCIEX Announces New Proteomics Tools for Biomarker Research.

Terms of use | Copyright © 2018 Farlex, Inc. | Feedback | For webmasters